ClinicalTrials.gg
RecruitingNCT07660354Updated Jun 22, 2026

Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

An interventional study of Medical Device (X92001483) in Lice; Head Lice, sponsored by Oystershell NV. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Oystershell NV · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Study summary

To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice

Read the detailed description

Compare Safety, Efficacy and preventative effect of a medical device with a physical mode of action against Nix Cream Rinse (1% Permethrin) in Subjects with Head Lice in a two-arm, randomized, controlled, Investigator/Assessor-blinded comparative study.

02

Conditions studied

  • Lice; Head Lice

Browse trials for

Keywords

  • Head Lice Treatment
03

In context

Lice Infestations

43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.

This study's planned enrollment of 98 is close to the median of 105 across 42 interventional studies indexed under Lice Infestations.

Browse Lice Infestations studies →

Lead sponsor

Oystershell NV is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: male / female.
  2. The subject or his/her parent/legal guardian (from age 12-17) must give written (after having been informed orally and by written text about the benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study). A caregiver must sign an informed consent agreement for children not old enough to do so. Children aged 6-11 years of age will be administered a child's assent form. The subject or his/her parent/legal guardian must be capable of understanding and providing written informed consent.
  3. Age ≥ 1 year of age at the time of enrollment.
  4. Subject agree to not use any other anti-lice or preventative treatment or medicated hair grooming products for the duration of the study (through last visit day- Day 14).
  5. Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 live nits based on magnified observations, present on the scalp and/or hair, as determined by a trained evaluator.
  6. The subject is in good general health based on medical history.
  7. Female subjects of must have a negative pregnancy test at screening and agree to use a reliable method of (as described in section 7.8) during duration of the study.
  8. The parent or legal guardian of a child subject must consent to the screening of other household members for head lice. If additional household members are found to have head lice and meet eligibility criteria, they must be enrolled in the study for all household members to qualify for participation.
  9. Have a single place of residence or agree to remain at the current residence for the duration of the study.
  10. Subject agrees not to additionally shampoo, wash, or rinse their hair or scalp for 24-hours post treatment.
  11. The subject agrees not to cut or chemically treat their hair while participating in the study.
  12. Subject agrees to follow all study instructions, including attending all follow-up appointments.

Exclusion criteria

Exclusion Criteria:

  1. Application of any form of head lice treatment, whether prescription or over-the counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
  2. Application of any topical medication of any kind on the hair or scalp for a period of 48 hours prior to the screening visit.
  3. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
  4. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
  5. History of allergy or to active ingredients, or constituents of the or comparator products.
  6. Subject with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the investigational product.
  7. Subjects with chronic scalp disorder.
  8. Subject or his/her legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and/or may be likely to exhibit poor compliance with the required visits.
  9. Females who are pregnant or nursing.
  10. Hair longer than waist length.
  11. Subject suspected or known not to follow instructions
  12. Previous participation in this study or participation in any other investigational trial within the preceding 14 days.
  13. The subject is directly affiliated to the investigator site personnel and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  14. The subject is an Oystershell employee or is an employee of a third-party organization involved in the study.
  15. People with dreadlocks or clips in hair that cannot be removed or a person who does not want to remove these.
  16. Hair that is too difficult to work with as assessed by the study staff.
  17. Families excluded where lice exist however a family member decline enrollment in the study.
  18. Subjects who are receiving, or are expected to receive, any antibiotic therapy during the study period will be excluded.
  19. No more than one working male subject per household may be excluded from evaluation if determined to be lice free by self-report or caregiver observation.
  20. All household members of the subject, other than excluded male adult, must be screened for head lice by a certified head lice professional. If additional household members are found to have head lice and meet the study criteria, they will be referred to LSRN Research and enrolled in study. If a household member declines enrollment, all family members will be excluded from the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    Medical Device X92001483

    Treatment of subjects with head Lice with the standard of care product Nix Creme Rinse on day 0 and day 7, followed by intermediate application of the medical device (X92001483) with a physical mode of action applied every 3 days.

    Device: Medical Device (X92001483)

  • No intervention
    Nix Cream Rinse (1% Permethrin)

    Treatment of subjects with Head Lice with Nix Cream Rinse (1% Permethrin) with a physical mode of action on day 0 and day 7.

Interventions

  • DeviceMedical Device (X92001483)

    Treatment of subjects with Head Lice with a medical device (X92001483) with a physical mode of action on day 0, day 7, day 10, day 13 and day 14.

06

What researchers measure

Primary outcomes

  1. Preventative Effect

    Determin whether subjects treated with the medical device X92001943 after treatment with Nix Creme Rinse maintain a higher cure rate at the end of the study compared with subjects treated only with Nix Creme Rinse.

    Time frame: 14 days

  2. Maintenance of cure rate over time

    To assess the maintenance of cure over time: To compare cure rates between subjects treated with Nix Creme Rinse and the medical device X92001483 at interim visits in order to evaluate the presence and persistence of the preventive effect of the investigational product relative to standard of care product (Nix creme rinse) alone.

    Time frame: day 3, day 7, day 10, day 13 and day 14

Secondary outcomes

  1. Time to re-infestation

    Characterize the time to re-infestation in each treatment group

    Time frame: 14 days

  2. Number of live lice

    To compare the number of live lice detected at each assessment across treatment groups.

    Time frame: Day 0, day 3, day 7, day 10, days 13, day 14

  3. Local tolerability

    To evaluate the local tolerability of the standard of care product and investigational product, as measured by subject reported symptoms (eg: burning, paraesthesia, pruritus) following application.

    Time frame: day 0, day 3, day 7, day 10, day 13 and day 14

  4. Scalp and skin irritation

    To evaluate scalp and skin irritation by study staff (secondary infection, erythema, excoriation) following product application.

    Time frame: day 0, day 3, day 4, day 7, day 10, day 13 and day 14

  5. Adverse advents

    To record and characterize all treatment-emergent adverse events occurring during the study.

    Time frame: Day 0, day 3, day 7, day 10, day 13 and day 14

07

Study locations

1 of 1 sites recruiting
  • LSRN
    Maitland, Florida 32751, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660354
Lead sponsor
Oystershell NV
Collaborators
LSRN Research
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
May 1, 2026
Primary completion
Sep 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 22, 2026

Study contacts

Katie Shepherd
Contact
katie@licesolutions.org
561-635-2884

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion